← Back to patent-cliff list
Leuprorelin depot(Camurus)
Tier C — Watch / tradeLeuprorelin depot(Camurus)
Camurus Ab
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GnRH
Indications (approved)：Prostate cancer
Regional status
US
-
EU
No progress
2014-09-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Leuprorelin depot(Camurus)?
Approved indications include: Prostate cancer.
When does the Leuprorelin depot(Camurus) patent expire?
No public expiry year is available for Leuprorelin depot(Camurus) yet; this page updates once verified.
How do I get a quote for Leuprorelin depot(Camurus) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12